Group items tagged

The current funding and contractual framework for community pharmacy is not fit for purpose, the Health and Social Care Committee report has concluded, recommending a complete overhaul to reduce its complexity. Published today, the report highlighted the necessity for a new framework to ensure adequate funding and to prevent damaging cross-subsidy between clinical services and prescription dispensing, as is presently observed. The report revealed that community pharmacy funding has fallen by over 30 per cent in real terms since 2015, resulting in an annual shortfall of at least £67,000 per pharmacy for individual owners. More than 1,100 community pharmacies have closed since 2015, of which were serving the most deprived areas, it said. MPs on the committee have urged the government to address medicine shortages, warning that they could undermine flagship initiatives such as 'Pharmacy First' by eroding public confidence in pharmacists. "People living with type 2 diabetes, ADHD, epilepsy and cystic fibrosis, and those experiencing the menopause, have faced challenges accessing the vital medication they need. Many others are facing similar experiences.

The Integrated Care Systems (ICSs) provide an opportunity to break the silo mentality in the health and care sector, National Pharmacy Association (NPA) chair Andrew Lane told MPs. While giving evidence to the Health and Social Care Select Committee on 6 December about the effectiveness of ICSs, Lane also poured cold water on newspaper reports that community pharmacists will be drafted in to break the NHS strike, as he reiterated the call for a "properly costed and funded environment." "We've been in different silos historically and ICSs are an opportunity to pull all systems together for the benefit of patients," he told committee members. Lane pointed to dementia-trained pharmacy delivery drivers and the Discharge Medicines Service as instances where the influence of community pharmacy already stretches beyond primary care into hospitals and social care. "We've seen pharmacists prescribe and get UTIs off doctors' desks, so we are starting to release capacity [in the system] and we're on that clinical journey. We welcome that, but it has to be with the right level of funding," he added.

The Department of Health and Social Care (DHSC) today (19 October) issued its official response to an evaluation conducted by an independent expert panel from the Health and Social Care Committee (HSCC) regarding government commitments in the pharmacy sector. The joint agreement between DHSC, NHSE, and CPE (Community Pharmacy England) under a five-year plan commitment to review the funding model, however, the current status is "continue to monitor and discuss progress". The government has claimed that the panel's rating has "not been met" and still "requires improvement". However, the funding "remains subject to affordability and consultation with the sector on the activity that can be delivered within that funding envelope".

Attempts to deal with record waiting lists for hospital treatment caused by the Covid-19 pandemic are at risk of being derailed by a staffing crisis, which is being exacerbated by the Omicron wave, a cross-party lawmakers' report said on Thursday (January 6). The report entitled 'Clearing the backlog caused by the pandemic' calls for a broader national health and care recovery plan - one that would embrace A&E, mental health, GPs, community and social care. Hospitals are facing extreme pressure as they try to catch up on months of operations that have been delayed and suspended during the pandemic, as Covid-19 hospitalizations rise once more and self-isolation hits staffing levels. There is a record 5.8 million waiting list for elective care, the Health and Social Care Committee said, adding that a recent surge in the Omicron variant has pushed cases to record highs and intensified pre-existing issues.

The Health and Social Care Committee (HSCC) has undertaken an inquiry into prevention and has published its first report of the series which focuses on vaccination. It has announced ten workstreams that will form the basis of inquiry, of which vaccination is one. HSCC said: "The UK has long been one of the world leaders on vaccination - one of the most successful and cost-effective preventative tools available. However, if challenges around uptake and bureaucratic processes in clinical trial set-up are not addressed, there is a very real risk that the UK's position as a global leader could be lost. This cannot be allowed to happen and in this report we set out some of the steps that we think will make a difference." It recommended a more flexible delivery model making use of a wider range of healthcare professionals. "The NHSE vaccination and immunisation strategy must have a strong focus on tackling practical challenges that limit vaccination access, make best use of a wider array of professionals, empower local leaders to pursue ways of addressing uptake in their own areas, and to set out guidance and examples of best practice around how voices other than NHSE can communicate important messaging around vaccination programmes," it suggested.

The Pharmaceutical Services Negotiating Committee (PSNC) has expressed its concerns over sustained pressures on medicines supply that are having a very serious impact on community pharmacy teams and their patients. It has asked contractors and their teams to continue using its regular reporting tools to help them demonstrate the scale of the problems to the Department of Health and Social Care (DHSC) and to support escalations as needed. The committee said: "The sustained increases in price concessions that we have seen so far in 2022 - with more than 100 concessions being granted in some months - show no signs of abating, and we know that many pharmacies now find themselves in a critical situation trying to source medicines in timely manner and facing significant financial risk due to greater uncertainty around expected reimbursement prices for a large number of medicines." "We know that some concessions being imposed by the Department do not match contractors' experience on the ground, and we would ask all contractors to continue reporting pricing issues to us on a regular basis to support our representations: Report product over Drug Tariff price."

The Pharmaceutical Services Negotiating Committee (PSNC) has challenged price concessions imposed by the Department of Health and Social Care (DHSC) on some of the medicines. It has raised concerns on the process for setting price concessions to senior government officials responsible for medicines supply, warning that the system is not working in the current environment from a community pharmacy contractor perspective. "When a new government takes over next week, this will be one of several urgent topics being raised by PSNC to new ministers, alongside the fuel price crisis, inflationary pressures and winter pressures on pharmacy businesses," said PSNC. The final update to August price concessions was announced yesterday taking the total concessions granted to a record 138 for August. PSNC said: "Of those, 99 were in line with PSNC requests, but prices for 39 lines were imposed by the Department of Health and Social Care (DHSC): those impositions do not match the purchase prices reported by contractors and the evidence of market prices which we passed on to DHSC. In particular, the final imposed prices of Apriprazole and Temazepam tablets has generated a lot of concern amongst contractors due to the large variation between their reimbursement prices and purchase prices during the month of August."

The Health and Social Care Committee (HSCC) has announced the appointment of six specialists to scrutinise the government's progress made on its commitments to pharmacy services in England on Wednesday (26 April). "They will work alongside the core members of the Expert Panel to produce a report evaluating Government progress across nine of the Government's own commitments across the four areas. A CQC-style rating from "inadequate" to "outstanding" will be awarded against each specific pledge with a final overall rating given," said DHSC. Professor Dame Jane Dacre, Chair of the Expert Panel, said: "The role of pharmacy in delivering care whether in hospital, the community or primary care has never been more important. "The Government has made a number of commitments aimed at improving pharmacy services and we'll be looking at the progress to achieve these targets. "In the process of our evaluation we'll be hearing from stakeholders from across the industry, including the pharmacy workforce and NHS and independent providers of pharmacy services. We'll be considering pledges covering frontline services as well as the education and training of the workforce." National Pharmacy Association (NPA) chief executive, Mark Lyonette, is one of six panel members with specialist expertise in pharmacy. They will work alongside five standing members who are all renowned healthcare policy experts and professionals. Professor Dame Jane Dacre will chair.

The Pharmaceutical Services Negotiating Committee announced last week that it is in discussions with the Department of Health and Social Care (DHSC) and NHS England about relieving capacity pressures, such as a relaxation of pharmacy opening hours requirements. PSNC is also scheduling webinars to talk with contactors about the steps they might be willing to take in future, to cut costs, should emergency financial relief fail to materialise. The pharmacy regulator reported that many of its members felt that it was no longer tenable for pharmacies to keep offering all of the free and non-core services to patients that they would like to, and that all contractors should consider what steps they could take to try to safeguard their businesses and their core services for patients. PSNC is also keen to talk to contractors about their current situation and the steps they might be willing to take in future, should emergency relief not be forthcoming.

The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the impact that high medicine price rises are having on contractor. Recently, the Department of Health and Social Care (DHSC) has granted the final list of price concessions for December 2022. The latest additions bring the total number of concessionary prices granted for the month of December to 198, surpassing the previous record of 159 granted in September 2022. PSNC has heard from hundreds of community pharmacy contractors who are paying inflated prices for antibiotics used for the treatment of Strep A and who have rightly been concerned about the lack of certainty around the final reimbursement prices for these medicines. It added: "We welcomed the involvement of the Competition and Markets Authority (CMA) to look into the pricing of antibiotics. But the number of reports we are getting from contractors about medicines price rises are just not acceptable and this goes far beyond the antibiotic crisis."

Pfizer has recalled all stocks of Accupro - including 5mg, 10mg, 20mg, 40mg film-coated tablets - as a precautionary measure due to the identification of a nitrosamine above the acceptable limit. "Following testing, N-nitroso-quinapril, has been observed at a level above the acceptable limit. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time. The recall is at pharmacy and wholesaler level," the Pharmaceutical Services Negotiating Committees (PSNC) reported. The Department of Health and Social Care (DHSC) said: "All strengths of quinapril (Accupro) tablets have been recalled with a resupply date to be confirmed. Pfizer are the sole supplier of quinapril tablets in the UK. Alternative ACE inhibitors remain available and can support an uplift in demand."

Any prescription for Promethazine hydrochloride 10mg tablets x 56 submitted for payment to the NHSBSA for July 2022 will be reimbursed at the new price of £17.77 not as per the price concession of £13.45 announced in the 4th concessions update published on 29 July 2022, said the Pharmaceutical Services Negotiating Committee (PSNC). In July 2022, PSNC received several reports from contractors unable to obtain Promethazine hydrochloride 10mg tablets (56) at the published Drug Tariff price of £4.24. Therefore, it submitted a request for a price concession, which was granted and subsequently published but this was later withdrawn after confirmation from the Department of Health and Social Care (DHSC) that due to the price change mechanism, the reimbursement price for Promethazine hydrochloride 10mg tablets has increased from £4.24 to £17.77 for July 2022. PSNC said, "Following the price change mechanism rules, for generic drugs (excluding drugs in Category M), a price change up to and including the 8th of the month takes effect for prescriptions dispensed in that same month. Any price change after the 8th takes place in the following month."

The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted the following price concessions for November 2021. Contractors can find information on the price concessions and learn about the process involved on PSNC's website. A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHSBSA to all items submitted for payment in the same month for which a price concession is granted. PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated November 2021 Drug Tariff price.

The Pharmaceutical Services Negotiating Committee (PSNC) has confirmed that the community pharmacy contractors are 'not required' to undertake a contractor-chosen or an NHS England determined clinical audit in 2023/24. "A clinical audit on anticoagulants is included in the Pharmacy Quality Scheme (PQS) 2023/24. If contractors choose to not participate in PQS, and therefore do not complete the anticoagulant clinical audit, there is still no requirement to complete two clinical audits in 2023/24," said PSNC. "The Department of Health and Social Care and NHS England have also committed to consider, during 2023/24, the removal of the requirement for a contractor-chosen clinical audit permanently."